Peptides DB
Research-centric peptide and protocol reference hub

ABS-201 record · updated 6h ago

Skin & aestheticsHealing & recoveryGrade A · human clinicalResearch use only
All 10 studiesJump to the evidenceCompare
What is ABS-201 used for?

ABS-201 is an investigational IgG1 monoclonal antibody that targets the prolactin receptor (PRLR), currently under clinical development for androgenetic alopecia (AGA). The mechanism of action involves the inhibition of PRLR signaling, which is thought to play a role in hair follicle biology and hair growth regulation. By blocking this receptor, ABS-201 may potentially alter the hair growth cycle and promote hair regrowth in individuals affected by AGA.

How it works: IgG1 monoclonal antibody targeting the prolactin receptor (PRLR), blocking prolactin signalling.

Primarily researched for · Skin & aestheticsRoute · Intravenous for single ascending doses and subcutaneous for multiple ascending doses in the Phase 1/2a trial. No established clinical route.

Development stage

where ABS-201 sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 2 registered trials. It describes the research record, not a recommendation.

Identity
NameABS-201
Chain length—
Molecular weight802 Da
FormulaC40H67N9O8
Structure typeNot established
ClassAesthetic
Research levelEmerging
Discovered byManually admitted · biologic, not a peptide · 2026

Mass and formula from PubChem CID 46866109. No verified residue count for this compound.

Pharmacology
MechanismIgG1 monoclonal antibody targeting the prolactin receptor (PRLR), blocking prolactin signalling.
RouteIntravenous for single ascending doses and subcutaneous for multiple ascending doses in the Phase 1/2a trial. No established clinical route.
Half-lifeEstimated at least 65 days per sponsor-reported interim Phase 1 data. Not peer reviewed.
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 5, 2026. How this works →
Research stats
Total studies10
Human / animal / cellular0 / 2 / 1
Highest trial phasePreclinical
Years covered2020–2026
Latest study16d ago
Publication history
20202026
Research funding
9,211 NIH projects · $36.9M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

10 rowsOpen in the library →
StudyTypeYearSummary depth
Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia-A Systematic Review with Network Meta-Analyses.
FindingNot reported in abstract.
review2026Full text read0.70
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.
FindingNot reported in abstract.
review2023Full text read0.80
Insightful Backbone Modifications Preventing Proteolytic Degradation of Neurotensin Analogs Improve NT<i>S1</i>-Induced Protective Hypothermia.
FindingSustained hypothermic effect of -3°C for at least 1 hour.
In vitro2020Full text read0.80
Pharmacological hypothermia induced neurovascular protection after severe stroke of transient middle cerebral artery occlusion in mice.
FindingNot reported in abstract.
Animal2020Full text read0.80
Targeted temperature management and early neuro-prognostication after cardiac arrest.
TakeawayTTM for at least 24 hours with slow rewarming is recommended post-cardiac arrest, but further research is needed to optimize its implementation.
review2021Full text read0.80
Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.
TakeawayAnti-EGFR nanocarriers hold promise for targeted cancer therapy, but further clinical validation is needed.
review2025Full text read0.90
A peptide-neurotensin conjugate that crosses the blood-brain barrier induces pharmacological hypothermia associated with anticonvulsant, neuroprotective, and anti-inflammatory properties following status epilepticus in mice.
FindingNot reported in abstract.
Animal2025Full text read0.80
Artificial intelligence-enabled precision medicine for inflammatory skin diseases.
TakeawayAI holds promise for advancing the diagnosis and treatment of inflammatory skin diseases, but its clinical integration requires careful validation.
review2026Full text read0.80
Emerging pharmacotherapies for androgenetic alopecia.
TakeawayEmerging therapies for androgenetic alopecia, including ABS-201, offer new mechanisms of action, but their clinical efficacy and safety need validation in future trials.
review2026Full text read0.70
Emerging pharmacotherapies for androgenetic alopecia.
TakeawayConfirms ABS-201 is in clinical development for androgenetic alopecia as a prolactin-receptor-targeting biologic. It contains no data on whether it works.
review2026Partial text0.60

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching ABS-201 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much ABS-201 is discussed should be drawn from it.